1. Home
  2. WOLF vs PHAR Comparison

WOLF vs PHAR Comparison

Compare WOLF & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wolfspeed Inc.

WOLF

Wolfspeed Inc.

HOLD

Current Price

$32.82

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$10.95

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WOLF
PHAR
Founded
1987
1988
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
WOLF
PHAR
Price
$32.82
$10.95
Analyst Decision
Sell
Strong Buy
Analyst Count
4
3
Target Price
$14.33
$38.33
AVG Volume (30 Days)
3.7M
7.8K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,385,982,000.00
N/A
Revenue This Year
N/A
$10.04
Revenue Next Year
$7.43
$2.51
P/E Ratio
N/A
$3,041.22
Revenue Growth
19.00
N/A
52 Week Low
$1.16
$9.62
52 Week High
$80.82
$21.34

Technical Indicators

Market Signals
Indicator
WOLF
PHAR
Relative Strength Index (RSI) 44.33 35.49
Support Level $15.86 $9.62
Resistance Level $31.99 $17.89
Average True Range (ATR) 2.43 0.48
MACD 0.83 -0.24
Stochastic Oscillator 63.12 32.54

Price Performance

Historical Comparison
WOLF
PHAR

About WOLF Wolfspeed Inc.

Wolfspeed Inc develops and manufactures semiconductor technologies based on silicon carbide (SiC) for power electronics applications. Its product portfolio includes SiC MOSFETs, Schottky diodes, and power modules used in power electronics applications. The company also provides reference designs, evaluation kits, and gate driver boards to support the development and integration of its SiC products across industries such as electric vehicles, renewable energy, and industrial systems.

About PHAR Pharming Group N.V.

Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.

Share on Social Networks: